Even if you’re not one to make New Year’s resolutions, the start of a new year naturally invites reflection on what worked well last year, what needs to change, and what to leave behind. With that spirit of looking ahead in mind, SleepWorld Magazine conducted its inaugural Reader Tech Survey […]
Other News
Why HST is Underutilized—and How to Fix It
As a sleep physician, one of the most frustrating realities I encounter is not a lack of diagnostic tools, but the barriers patients face in accessing them. Obstructive sleep apnea (OSA) is common, serious, and widely underdiagnosed. Estimates suggest that more than 30 million adults in the United States are […]
Alkermes Announces Phase 3 Brilliance Studies Evaluating Alixorexton for Narcolepsy Type 1 and Type 2
Alkermes plc, announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development […]
Sleep Physician Sentenced for CPAP Fraud Case
On March 25, United States District Court Judge Rebecca L. Pennell sentenced Dr. Eric Edward Haeger, age 57, of Brewster, Washington, to one year and a day in federal prison followed by a one-year term of supervised release after Haeger pleaded guilty to adulterating and misbranding medical devices with the […]
Eisai to Begin Enrolling Phase 2 Study in Patients With Narcolepsy
Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, […]
Lilly to Acquire Centessa to Advance Treatments for Sleep-Wake Disorders
Eli Lilly and Company and Centessa Pharmaceuticals plc, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Lilly to acquire Centessa. Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to […]
Researchers Find Autoimmune Evidence for Narcolepsy
Narcolepsy is a chronic condition in which someone feels excessively sleepy, occasionally falling asleep without warning. This can have a major impact on their daily lives, affecting not only their education and employment, but also their ability to drive, their relationships, and their emotional health. “It’s quite striking when you’re […]
AI Could Help NHS Clinicians Diagnose Childhood Sleep Apnea, Study Finds
AI software designed to help diagnose sleep apnea in children has achieved high accuracy in an NHS trial, with the findings independently reviewed by clinical specialists. Glasgow company Seluna tested its autoscoring and sleep staging software on 500 retrospective sleep studies from NHS Greater Glasgow and Clyde’s Royal Hospital for […]
LivaNova Receives U.S. FDA Premarket Approval for aura6000 System to Treat Moderate to Severe OSA
LivaNova PLC announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with […]
Robert Wood Johnson University Hospital Expands Sleep Testing Capacity by 290% After Implementing Wesper Dropship Model
Wesper announces Robert Wood Johnson University Hospital (RWJUH) Somerset has expanded monthly sleep testing capacity by 290% following the adoption of Wesper’s direct-to-patient, dropship home sleep testing model, according to a newly released whitepaper detailing the operational transformation. Prior to implementation, RWJUH Somerset faced growing demand for sleep apnea testing […]













